3B Blackbio (3BBLACKBIO) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2025Income Metrics
Revenue
964.7M
Gross Profit
708.2M
73.42%
Operating Income
490.2M
50.82%
Net Income
476.9M
49.44%
Balance Sheet Metrics
Total Assets
3.0B
Total Liabilities
247.1M
Shareholders Equity
2.7B
Debt to Equity
0.09
Cash Flow Metrics
Operating Cash Flow
620.0M
Free Cash Flow
424.5M
Revenue & Profitability Trend
3B Blackbio Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 964.7M | 741.2M | 618.4M | 806.5M | 2.3B |
| Cost of Goods Sold | 256.5M | 218.5M | 179.2M | 316.2M | 515.7M |
| Gross Profit | 708.2M | 522.8M | 439.1M | 490.2M | 1.8B |
| Operating Expenses | 133.9M | 119.3M | 90.3M | 71.1M | 168.1M |
| Operating Income | 490.2M | 322.4M | 286.3M | 364.3M | 1.5B |
| Pre-tax Income | 640.0M | 443.3M | 353.1M | 432.2M | 1.5B |
| Income Tax | 163.1M | 122.3M | 93.7M | 110.2M | 381.7M |
| Net Income | 476.9M | 321.0M | 259.4M | 322.0M | 1.1B |
| EPS (Diluted) | - | ₹37.46 | ₹30.27 | ₹43.40 | ₹151.66 |
Income Statement Trend
3B Blackbio Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 1.3B | 1.2B | 1.1B | 815.4M | 1.2B |
| Non-Current Assets | 1.6B | 1.2B | 998.2M | 1.1B | 751.4M |
| Total Assets | 3.0B | 2.5B | 2.1B | 1.9B | 1.9B |
| Liabilities | |||||
| Current Liabilities | 185.9M | 175.3M | 141.8M | 169.0M | 429.6M |
| Non-Current Liabilities | 61.3M | 51.0M | 39.6M | 31.1M | 22.8M |
| Total Liabilities | 247.1M | 226.3M | 181.5M | 200.2M | 452.5M |
| Equity | |||||
| Total Shareholders Equity | 2.7B | 2.3B | 2.0B | 1.7B | 1.5B |
Balance Sheet Composition
3B Blackbio Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 640.0M | 443.3M | 353.1M | 432.2M | 1.5B |
| Operating Cash Flow | 620.0M | 342.7M | 331.3M | 739.8M | 989.1M |
| Investing Activities | |||||
| Capital Expenditures | -9.0M | -5.1M | -20.2M | -22.6M | -16.8M |
| Investing Cash Flow | -338.5M | -203.2M | 124.9M | -360.8M | -702.6M |
| Financing Activities | |||||
| Dividends Paid | -25.7M | -21.9M | -44.4M | -154.6M | - |
| Financing Cash Flow | -31.1M | -37.0M | -48.7M | -149.6M | -13.4M |
| Free Cash Flow | 424.5M | 264.4M | 182.6M | 350.6M | 958.4M |
Cash Flow Trend
3B Blackbio Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
28.74
Price to Book
5.34
Price to Sales
14.24
Profitability Ratios
Profit Margin
49.44%
Operating Margin
33.96%
Return on Equity
19.21%
Return on Assets
11.27%
Financial Health
Current Ratio
7.11
Debt to Equity
0.11
Beta
1.07
Per Share Data
EPS (TTM)
₹55.67
Book Value per Share
₹299.81
Revenue per Share
₹112.59
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| 3bblackbio | 13.7B | 28.74 | 5.34 | 19.21% | 49.44% | 0.11 |
| Biocon | 492.9B | 43.71 | 2.04 | 5.40% | 6.64% | 66.26 |
| OneSource Specialty | 229.1B | - | 3.89 | -0.55% | -1.24% | 16.03 |
| Dishman Carbogen | 40.6B | 1,233.57 | 0.70 | 0.06% | 0.12% | 40.97 |
| Zota Health Care | 33.3B | - | 20.32 | -24.83% | -20.55% | 65.72 |
| Panacea Biotec | 25.7B | 91.93 | 3.06 | -1.05% | -1.50% | 2.67 |
Financial data is updated regularly. All figures are in the company's reporting currency.